Viral hemorrhagic fevers: advancing the level of treatment

BMC Medicine

Emanuele Nicastri¹  Maria Rosaria Capobianchi¹  Antonino Di Caro¹  Francesco Vairo³  Simone Lanini¹  Heinz Feldmann²  Giuseppe Ippolito¹ 

[1] National Institute for Infectious Diseases Lazzaro Spallanzani, Via Portuense 292 00149 Rome, Italy;Laboratory of Virology, Division of Intramural Research, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, 903 South 4th Street, Hamilton, MT 59840, USA;Italian Health Cooperation, Piazzale della Farnesina 1 00135 Rome, Italy

关键词: viral hemorrhagic fever;    innovative therapeutics;    clinical management;   

Others  :  1126272
DOI  :  10.1186/1741-7015-10-31

 received in 2011-11-14, accepted in 2012-03-29,  发布年份 2012

【 摘 要 】

The management of viral hemorrhagic fevers (VHFs) has mainly focused on strict infection control measures, while standard clinical interventions that are provided to patients with other life-threatening conditions are rarely offered to patients with VHFs. Despite its complexity, a proper clinical case management of VHFs is neither futile nor is it lacking in scientific rationale. Given that patient outcomes improve when treatment is started as soon as possible, development and implementation of protocols to promptly identify and treat patients in the earliest phases of diseases are urgently needed. Different pharmacological options have been proposed to manage patients and, as for other life-threatening conditions, advanced life support has been proved effective to address multiorgan failure. In addition, high throughput screening of small molecular libraries has emerged as a novel promising way to find new candidates drugs for VHFs therapy and a relevant number of new molecules are currently under investigation. Here we discuss the current knowledge about VHF clinical management to propose a way to step up the approach to VHFs beyond the mere application of infection control measures.

【 授权许可】

   
2012 Ippolito et al; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Ippolito G, Fusco FM, Di Caro A, Nisii C, Pompa MG, Thinus G, Pletschette M, Capobianchi MR: Facing the threat of highly infectious diseases in Europe: the need for a networking approach. Clin Microbiol Infect 2009, 15:706-710.
• [2]Brouqui P, Puro V, Fusco FM, Bannister B, Schilling S, Follin P, Gottschalk R, Hemmer R, Maltezou HC, Ott K, Peleman R, Perronne C, Sheehan G, Siikamäki H, Skinhoj P, Ippolito G, EUNID Working Group: Infection control in the management of highly pathogenic infectious diseases: consensus of the European Network of Infectious Disease. Lancet Infect Dis 2009, 9:301-311.
• [3]Bannister B, Puro V, Fusco FM, Heptonstall J, Ippolito G, EUNID Working Group: Framework for the design and operation of high-level isolation units: consensus of the European Network of Infectious Diseases. Lancet Infect Dis 2009, 9:45-56.
• [4]Sterk E: Filovirus Haemorrhagic Fever Guideline. Paris, France: Médecins Sans Frontières; 2008.
• [5]Ergonul O: Treatment of Crimean-Congo hemorrhagic fever. Antiviral Res 2008, 78:125-131.
• [6]Feldmann H, Geisbert TW: Ebola haemorrhagic fever. Lancet 2011, 377:849-862.
• [7]World Health Organization: WHO recommended surveillance standards, Second edition 2009. [http:/ / www.who.int/ csr/ resources/ publications/ surveillance/ WHO_CDS_CSR_ISR_99_2_EN/ en/ ] webcite
• [8]Pittalis S, Fusco FM, Lanini S, Nisii C, Puro V, Lauria FN, Ippolito G: Case definition for Ebola and Marburg haemorrhagic fevers: a complex challenge for epidemiologists and clinicians. New Microbiol 2009, 32:359-367.
• [9]Trombley AR, Wachter L, Garrison J, Buckley-Beason VA, Jahrling J, Hensley LE, Schoepp RJ, Norwood DA, Goba A, Fair JN, Kulesh DA: Comprehensive panel ofreal-time TaqMan polymerase chain reaction assays for detection and absolute quantification of filoviruses, arenaviruses, and New World hantaviruses. Am JTrop Med Hyg 2010, 82:954-960.
• [10]Palacios G, Briese T, Kapoor V, Jabado O, Liu Z, Venter M, Zhai J, Renwick N, Grolla A, Geisbert TW, Drosten C, Towner J, Ju J, Paweska J, Nichol ST, Swanepoel R, Feldmann H, Jahrling PB, Lipkin WI: MassTag polymerase chain reaction for differential diagnosis of viral hemorrhagic fever. Emerg Infect Dis 2006, 12:692-695.
• [11]Zhai J, Palacios G, Towner JS, Jabado O, Kapoor V, Venter M, Grolla A, Briese T, Paweska J, Swanepoel R, Feldmann H, Nichol ST, Lipkin WI: Rapid molecular strategy for filovirus detection and characterization. J Clin Microbiol 2007, 45:224-226.
• [12]Poloni TR, Oliveira AS, Alfonso HL: Detection of dengue virus in saliva and urine by real time RT-PCR. Virol J 2010, 7:22. BioMed Central Full Text
• [13]Bodur H, Akinci E, Ongürü P, Carhan A, Uyar Y, Tanrici A, Cataloluk O, Kubar : Detection of Crimean-Congo hemorrhagic fever virus genome in saliva and urine. Int J Infect Dis 2010, 14:e247-249.
• [14]Formenty P, Leroy EM, Epelboin A, Libama F, Lenzi M, Sudeck H, Yaba P, Allarangar Y, Boumandouki P, Nkounkou VB, Drosten C, Grolla A, Feldmann H, Roth C: Detection of Ebola virus in oral fluid specimens during outbreaks of Ebola virus hemorrhagic fever in the Republic of Congo. Clin Infect Dis 2006, 42:1521-1526.
• [15]Domingo C, Yactayo S, Agbenu E Demanou M, Schulz AR, Daskalow K, Niedrig M: Detection of yellow fever 17D genome in urine. J Clin Microbiol 2011, 49:760-762.
• [16]Grolla A, Jones SM, Fernando L, Strong JE, Ströher U, Möller P, Paweska JT, Burt F, Pablo Palma P, Sprecher A, Formenty P, Roth C, Feldmann H: The use of amobile laboratory unit in support of patient management and epidemiological surveillance during the 2005 Marburg Outbreak in Angola. PLoS Negl Trop Dis 2011, 5:e1183.
• [17]Pettersson L, Klingström J, Hardestam J, Lundkvist A, Ahlm C, Evander M: Hantavirus RNA in saliva from patients with hemorrhagic fever with renal syndrome. Emerg Infect Dis 2008, 14:406-411.
• [18]Feldmann H, Jones SM, Daddario-DiCaprio KM, Geisbert JB, Ströher U, Grolla A, Bray M, Fritz EA, Fernando L, Feldmann F, Hensley LE, Geisbert TW: Effective post exposure treatment of Ebola infection. PLoS Pathog 2007, 3:e2.
• [19]Geisbert TW, Daddario-DiCaprio KM, Williams KJ, Geisbert JB, Leung A, Feldmann F, Hensley LE, Feldmann H, Jones SM: Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol 2008, 82:5664-5668.
• [20]Geisbert TW, Hensley LE, Geisbert JB, Leung A, Johnson JC, Grolla A, Feldmann H: Postexposure treatment of Marburg virus infection. Emerg Infect Dis 2010, 16:1119-1122.
• [21]Tuffs A: Experimental vaccine may have saved Hamburg scientist from Ebola fever. BMJ 2009, 338:b1223.
• [22]Papa A, Bozovi B, Pavlidou V: Genetic detection and isolation of Crimean-Congo hemorrhagic fever virus, Kosovo, Yugoslavia. Emerg Infect Dis 2002, 8:852-854.
• [23]Enria DA, Briggiler AM, Fernandez NJ, Levis SC, Maiztegui JI: Importance of dose of neutralising antibodies in treatment of Argentine haemorrhagic fever with immune plasma. Lancet 1984, 2:255-256.
• [24]Hoogstraal H: The epidemiology of tick-borne Crimean-Congo hemorrhagic fever in Asia, Europe, and Africa. J Med Entomol 1979, 15:307-417.
• [25]Enria DA, Briggiler AM, Sánchez Z: Treatment of Argentine hemorrhagic fever. Antiviral Res 2008, 78:132-139.
• [26]Vassilenko SM, Vassilev TL, Bozadjiev LG, Bineva IL, Kazarov GZ: Specific intravenous immunoglobulin for Crimean-Congo haemorrhagic fever. Lancet 1990, 335:791-792.
• [27]Mupapa K, Massamba M, Kibadi K, Kuvula K, Bwaka A, Kipasa M, Colebunders R, Muyembe-Tamfum JJ: Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. J Infect Dis 1999, 179(Suppl 1):18-23.
• [28]Jahrling PB, Geisbert JB, Swearengen JR, Larsen T, Geisbert TW: Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. J Infect Dis 2007, 196(Suppl 2):400-403.
• [29]Nakayama E, Tomabechi D, Matsuno K, Kishida N, Yoshida R, Feldmann H, Takada A: Antibody-dependent enhancement of Marburg virus infection. J Infect Dis 2011, 204(Suppl 3):978-985.
• [30]Moi ML, Lim CK, Kotaki A, Takasaki T, Kurane I: Development of an antibody-dependent enhancement assay for dengue virus using stable BHK-21 cell lines expressing Fc gammaRIIA. J Virol Methods 2010, 163:205-209.
• [31]Geisbert TW, Hensley LE, Kagan E, Yu EZ, Geisbert JB, Daddario-DiCaprio K, Fritz EA, Jahrling PB, McClintock K, Phelps JR, Lee AC, Judge A, Jeffs LB, MacLachlan I: Postexposure protection of guinea pigs against a lethal Ebola virus challenge is conferred by RNA interference. J Infect Dis 2006, 193:1650-1657.
• [32]Geisbert TW, Lee AC, Robbins M, Geisbert JB, Honko AN, Sood V, Johnson JC, de Jong S, Tavakoli I, Judge A, Hensley LE, Maclachlan I: Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 2010, 375:1896-1905.
• [33]Bossi P, Tegnell A, Baka A, Van Loock F, Hendriks J, Werner A, Maidhof H, Gouvras G, Task Force on Biological and Chemical Agent Threats, Public Health Directorate, European Commission, Luxembourg: Bichat guidelines for the clinical management of haemorrhagic fever viruses and bioterrorism-related haemorrhagic fever viruses. Euro Surveill 2004, 9:E11-12.
• [34]McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, Johnson KM, Elliott LH, Belmont-Williams R: Lassa fever: effective therapy with ribavirin. N Engl J Med 1986, 314:20-26.
• [35]Holmes GP, McCormick JB, Trock SC, Chase RA, Lewis SM, Mason CA, Hall PA, Brammer LS, Perez-Oronoz GI, McDonnell MK: Lassa fever in the United States. Investigation of a case and new guidelines for management. N Engl J Med 1990, 323:1120-1123.
• [36]Huggins JW, Hsiang CM, Cosgriff TM, Guang MY, Smith JI, Wu ZO, LeDuc JW, Zheng ZM, Meegan JM, Wang QN: Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J Infect Dis 1991, 164:1119-1127.
• [37]Paragas J, Whitehouse CA, Endy TP, Bray M: A simple assay for determining antiviral activity against Crimean-Congo hemorrhagic fever virus. Antiviral Res 2004, 62:21-25.
• [38]Sharifi-Mood B, Metanat M, Ghorbani-Vaghei A, Fayyaz-Jahani F, Akrami E: The outcome of patients with Crimean-Congo hemorrhagic fever in Zahedan, southeast of Iran: a comparative study. Arch Iran Med 2009, 12:151-153.
• [39]Koksal I, Yilmaz G, Aksoy F, Aydin H, Yavuz I, Iskender S, Akcay K, Erensoy S, Caylan R, Aydin K: The efficacy of ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Eastern Black Sea region in Turkey. J Clin Virol 2010, 47:65-68.
• [40]Koksal I, Yilmaz G, Aksoy F, Aydin H, Yavuz I, Iskender S, Akcay K, Erensoy S, Caylan R, Aydin K: T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res 2009, 82:95-102.
• [41]Aman MJ, Kinch MS, Warfield K, Warren T, Yunus A, Enterlein S, Stavale E, Wang P, Chang S, Tang Q, Porter K, Goldblatt M, Bavari S: Development of a broad-spectrum antiviral with activity against Ebola virus. Antiviral Res 2009, 83:245-251.
• [42]Lee AM, Pasquato A, Kunz S: Novel approaches in anti-arenaviral drug development. Virology 2011, 411:163-169.
• [43]Shum D, Smith JL, Hirsch AJ, Bhinder B, Radu C, Stein DA, Nelson JA, Früh K, Djaballah H: High-content assay to identify inhibitors of dengue virus infection. Assay Drug Dev Technol 2010, 8:553-570.
• [44]Bolken TC, Laquerre S, Zhang Y, Bailey TR, Pevear DC, Kickner SS, Sperzel LE, Jones KF, Warren TK, Amanda Lund S, Kirkwood-Watts DL, King DS, Shurtleff AC, Guttieri MC, Deng Y, Bleam M, Hruby DE: Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses. Antivir Res 2006, 69:86-97.
• [45]Basu A, Li B, Mills DM, Panchal RG, Cardinale SC, Butler MM, Peet NP, Majgier-Baranowska H, Williams JD, Patel I, Moir DT, Bavari S, Ray R, Farzan MR, Rong L, Bowlin TL: Identification of a small-molecule entry inhibitor for filoviruses. J Virol 2011, 85:3106-3119.
• [46]Urata S, Yun N, Pasquato A, Paessler S, Kunz S, de la Torre JC: Antiviral activity of a small-molecule inhibitor of arenavirus glycoprotein processing by the cellular site 1 protease. J Virol 2011, 85:795-803.
• [47]Pasquato A, Rochat C, Burri DJ, Pasqual G, de la Torre JC, Kunz S: Evaluation of the anti-arenaviral activity of the subtilisin kexin isozyme-1/site-1 protease inhibitor PF-429242. Virology 2012, 423:14-22.
• [48]Vincent MJ, Sanchez AJ, Erickson BR, Basak A, Chretien M, Seidah NG, Nichol ST: Crimean-Congo hemorrhagic fever virus glycoprotein proteolytic processing by subtilase SKI-1. J Virol 2003, 77:8640-8649.
• [49]Geisbert TW, Hensley LE, Jahrling PB, Larsen T, Geisbert JB, Paragas J, Young HA, Fredeking TM, Rote WE, Vlasuk GP: Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 2003, 362:1953-1958.
• [50]Hensley LE, Stevens EL, Yan SB, Geisbert JB, Macias WL, Larsen T, Daddario-DiCaprio KM, Cassell GH, Jahrling PB, Geisbert TW: Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J Infect Dis 2007, 196(Suppl 2):390-399.
• [51]Rankin LG, Austin DL: The use of activated protein C in severe Plasmodium falciparum malaria. Anaesth Intensive Care 2007, 3:428-32.
• [52]Souza DG, Fagundes CT, Sousa LP, Amaral FA, Souza RS, Souza AL, Kroon EG, Sachs D, Cunha FQ, Bukin E, Atrasheuskaya A, Ignatyev G, Teixeira MM: Essential role of platelet-activating factor receptor in the pathogenesis of Dengue virus infection. Proc Natl Acad Sci USA 2009, 106:14138-14143.
• [53]Assunção-Miranda I, Amaral FA, Bozza FA, Fagundes CT, Sousa LP, Souza DG, Pacheco P, Barbosa-Lima G, Gomes RN, Bozza PT, Da Poian AT, Teixeira MM, Bozza MT: Contribution of macrophage migration inhibitory factor to the pathogenesis of dengue virus infection. FASEB J 2010, 24:218-228.
• [54]Chen LC, Lei HY, Liu CC, Shiesh SC, Chen SH, Liu HS, Lin YS, Wang ST, Shyu HW, Yeh TM: Correlation of serum levels of macrophage migration inhibitory factor with disease severity and clinical outcome in dengue patients. Am J Trop Med Hyg 2006, 74:142-147.
• [55]Michelow IC, Dong M, Mungall BA, Yantosca LM, Lear C, Ji X, Karpel M, Rootes CL, Brudner M, Houen G, Eisen DP, Kinane TB, Takahashi K, Stahl GL, Olinger GG, Spear GT, Ezekowitz RA, Schmidt EV: A novel l-ficolin/mannose-binding lectinchimeric molecule with enhanced activity against Ebola virus. J Biol Chem 2010, 285:24729-24739.
• [56]Seitsonen E, Hynninen M, Kolho E, Kallio-Kokko H, Pettilä V: Corticosteroids combined with continuous veno-venous hemodiafiltration for treatment of hantavirus pulmonary syndrome caused by Puumala virus infection. Eur J Clin Microbiol Infect Dis 2006, 25:261-266.
• [57]Krause R, Aberle S, Haberl R, Daxböck F, Wenisch C: Puumala virus infection with acute disseminated encephalomyelitis and multiorgan failure. Emerg Infect Dis 2003, 9:603-605.
• [58]Chang B, Crowley M, Campen M, Koster F: Hantavirus cardiopulmonary syndrome. Semin Respir Crit Care Med 2007, 28:193-200.
• [59]Dietl CA, Wernly JA, Pett SB, Yassin SF, Sterling JP, Dragan R, Milligan K, Crowley MR: Extracorporeal membrane oxygenation support improves survival of patients with severe Hantavirus cardiopulmonary syndrome. J Thorac Cardiovasc Surg 2008, 135:579-584.
• [60]Pipeling MR, Fan E: Therapies for refractory hypoxemia in acute respiratory distress syndrome. JAMA 2010, 304:2521-2527.
• [61]Senior K: European lab network prepares for high-risk pathogen threat. Lancet Infect Dis 2008, 8:593.
• [62]Sanchez A, Geisbert TW, Feldmann H: Filoviridae: Marburg and Ebola viruses. In Fields virology. 5th edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:1409-1448.
• [63]Ippolito G, Nisii C, Capobianchi MR: Networking for infectious-disease emergencies in Europe. Nature Rev Microbiol 2008, 6:564.